{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:35:45Z","timestamp":1774416945725,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011167","name":"Australasian College of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejca.2020.10.013","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T11:08:54Z","timestamp":1605438534000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-243X","authenticated-orcid":false,"given":"Angela M.","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora","family":"Waldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brindha","family":"Shivalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-2496","authenticated-orcid":false,"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.013_bib1","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.10.013_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/bjc.2011.178","article-title":"Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens","volume":"104","author":"Chiarion-Sileni","year":"2011","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.10.013_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.10.013_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib5","unstructured":"Cancer Council Australia Melanoma Guidelines Working Party. Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. [cited 2020 Mar 1]."},{"key":"10.1016\/j.ejca.2020.10.013_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ans.15138","article-title":"Multidisciplinary care of cancer patients: a passing fad or here to stay?","volume":"89","author":"Thompson","year":"2019","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.ejca.2020.10.013_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.013_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.surneu.2009.03.005","article-title":"Factors affecting the outcome after treatment for metastatic melanoma to the brain","volume":"72","author":"Carrubba","year":"2009","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ejca.2020.10.013_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3171\/2011.3.JNS091107","article-title":"Surgical management of melanoma brain metastases in patients treated with immunotherapy","volume":"115","author":"Lonser","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.10.013_bib10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.clineuro.2013.03.019","article-title":"Intracerebral metastases of malignant melanoma and their recurrences\u2014a clinical analysis","volume":"115","author":"Miller","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ejca.2020.10.013_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10143-011-0348-z","article-title":"Single brain metastases from melanoma: remarks on a series of 84 patients","volume":"35","author":"Salvati","year":"2012","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.ejca.2020.10.013_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3171\/jns.2002.96.3.0552","article-title":"Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades","volume":"96","author":"Zacest","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.10.013_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1748-717X-9-155","article-title":"Stereotactic radiosurgery (SRS) for brain metastases: a systematic review","volume":"9","author":"Nieder","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib14","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/0973-1482.98973","article-title":"Linear accelerator based stereotactic radiosurgery for melanoma brain metastases","volume":"8","author":"Bernard","year":"2012","journal-title":"J Canc Res Therapeut"},{"key":"10.1016\/j.ejca.2020.10.013_bib16","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.4103\/2152-7806.163315","article-title":"Stereotactic radiosurgery for brain metastases from malignant melanoma","volume":"6","author":"Christ","year":"2015","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.ejca.2020.10.013_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.10.013_bib18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.19.01414","article-title":"Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib19","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2020.10.013_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.ejca.2020.10.013_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3171\/2010.8.GKS10994","article-title":"Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?","volume":"113","author":"Chang","year":"2010","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2020.10.013_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijrobp.2011.12.009","article-title":"Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control","volume":"84","author":"Choi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2020.10.013_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1227\/NEU.0000000000000584","article-title":"Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection","volume":"76","author":"Ling","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2020.10.013_bib28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib30","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.013_bib31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.013_bib32","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.013_bib33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.10.013_bib34","first-page":"361","article-title":"ERICA predicts response to tamoxifen in elderly women with breast cancer","volume":"73","author":"Davies","year":"1991","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.ejca.2020.10.013_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib36","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib37","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1805453","article-title":"Nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.013_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib40","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4161\/onci.20687","article-title":"Ipilimumab in a Phase II trial of melanoma patients with brain metastases","volume":"1","author":"Margolin","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2020.10.013_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib42","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib43","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9600","article-title":"A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial)","volume":"37","author":"Gonzalez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib45","first-page":"1021","article-title":"Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques","volume":"56","author":"Paek","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2020.10.013_bib46","doi-asserted-by":"crossref","first-page":"8708","DOI":"10.3390\/ijms14058708","article-title":"Surgical resection of brain metastases-impact on neurological outcome","volume":"14","author":"Schodel","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2020.10.013_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-015-1932-9","article-title":"Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease","volume":"125","author":"Bates","year":"2015","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2020.10.013_bib48","first-page":"5079","article-title":"Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes","volume":"34","author":"Rades","year":"2014","journal-title":"Anticancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:11Z","timestamp":1760732951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920312727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"alternative-id":["S0959804920312727"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}